Skip to main content

Table 2 Baseline echocardiographic findings

From: Left atrial longitudinal strain as a predictor of Cancer therapeutics-related cardiac dysfunction in patients with breast Cancer

 

CTRCD (n = 13)

No CTRCD (n = 59)

p value

LVEDVI (mL/m2)

56.8 ± 10.6

56.5 ± 9.9

0.920

LVESVI (mL/m2)

19.9 ± 5.3

20.3 ± 4.6

0.774

LVEF (%)

65.0 ± 6.4

63.9 ± 5.9

0.564

LVGLS (%)

−21.0 ± 2.4

−22.2 ± 2.2

0.086

E (cm/sec)

71.3 ± 10.4

62.7 ± 7.7

0.001

e’ (cm/sec)

8.8 ± 1.4

8.3 ± 1.8

0.379

s’ (cm/sec)

7.9 ± 0.9

7.4 ± 1.0

0.138

E/e’

8.2 ± 1.0

7.7 ± 1.2

0.201

LAVI (mL/m2)

25.8 ± 3.8

26.0 ± 3.9

0.833

PALS (%)

33.1 ± 5.9

33.8 ± 5.6

0.689

LA conduit strain (%)

19.2 ± 3.4

19.8 ± 3.3

0.550

LA booster strain (%)

13.9 ± 2.5

14.0 ± 2.3

0.905

RVSP (mmHg)

29.3 ± 7.1

32.0 ± 7.3

0.239

  1. CTRCD cancer therapeutics-related cardiac dysfunction, LVEDVI left ventricular end-diastolic volume index, LVESVI left ventricular end-systolic volume index, LVEF left ventricular ejection fraction, LVGLS left ventricular global longitudinal strain, E early diastolic mitral inflow velocity, e’: early diastolic velocity of mitral septal annulus, s’: systolic velocity of mitral septal annulus, LAVI left atrial volume index, PALS peak atrial longitudinal strain, LA left atrium, RVSP right ventricular systolic pressure